Coya Therapeutics secures FDA fast track status for COYA 302

Coya Therapeutics has received fast track designation from the US FDA for COYA 302, an investigational biologic combination therapy to treat ALS. COYA 302 is a proprietary biologic combination therapy that utilises a dual immunomodulatory approach. COYA 302 is being developed for subcutaneous administration in ALS patients, with mechanisms potentially offering additive or synergistic effects. Credit: Phalexaviles/Shutterstock.com. Coya Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for COYA 302, an investigational biologic combination therapy being developed to treat amyotrophic lateral sclerosis (ALS). The designation is intended to expedite the development and review processes for…

Source: Pharmaceutical Technology